Advertisement

Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis

Published:September 07, 2015DOI:https://doi.org/10.1016/j.ncl.2015.07.008

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Neurologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Available at: http://www.nlm.nih.gov/medlineplus/complementaryandalternativemedicine.html. Accessed February 21, 2015.

        • Wasner M.
        • Klier H.
        • Borasio G.
        The use of alternative medicine by patients with amyotrophic lateral sclerosis.
        J Neurol Sci. 2001; 191: 151-154
        • Vardeny O.
        • Bromberg M.
        The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis.
        J Herb Pharmacother. 2005; 5: 23-31
        • Miller R.G.
        • Jackson C.E.
        • Kasarskis J.
        • et al.
        Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
        Neurology. 2009; 73: 1218-1226
        • Miller R.G.
        • Jackson C.E.
        • Kasarskis J.
        • et al.
        Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review).
        Neurology. 2009; 73: 1227-1233
        • Karam C.
        • Paganoni S.
        • Joyce N.
        • et al.
        Palliative care issues in amyotrophic lateral sclerosis: an evidence based review.
        Am J Hosp Palliat Care. 2014; ([Epub ahead of print])
      2. Available at: https://www.google.com/#q=als+treatment. Accessed February 17, 2015.

        • Chew S.
        • Khandji A.
        • Montes J.
        • et al.
        Olfactory ensheathing glia injections in Beijing: misleading patients with ALS.
        Amyotroph Lateral Scler. 2007; 8: 314-316
        • Piepers S.
        • Van Den Berg L.
        No benefits from experimental treatment with olfactory ensheathing cells in patients with ALS.
        Amyotroph Lateral Scler. 2010; 11: 328-330
        • Bedlack R.S.
        • Pastula D.M.
        • Welsh E.
        • et al.
        Scrutinizing enrollment in ALS trials: room for improvement?.
        Amyotroph Lateral Scler. 2008; 9: 257-265
        • Kasarskis E.J.
        • Berryman S.
        • Vanderleest J.G.
        • et al.
        Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death.
        Am J Clin Nutr. 1996; 63: 130-137
        • Desport J.C.
        • Preux P.M.
        • Truong C.T.
        • et al.
        Nutritional assessment and survival in ALS patients.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1: 91-96
        • Heffernan C.
        • Jenkinson C.
        • Holmes T.
        • et al.
        Nutritional management in MND/ALS patients: an evidence based review.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5: 72-83
        • Pedersen W.A.
        • Mattson M.P.
        No benefit of dietary restriction on disease onset or progression in amyotrophic lateral sclerosis Cu/Zn-superoxide dismutase mutant mice.
        Brain Res. 1999; 833: 117-120
        • Hamadeh M.J.
        • Rodriguez M.C.
        • Kaczor J.J.
        • et al.
        Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse.
        Muscle Nerve. 2005; 31: 214-220
        • Zhao Z.
        • Sui Y.
        • Gao W.
        • et al.
        Effects of diet on adenosine monophosphate-activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model.
        J Int Med Res. 2015; 43: 67-79
        • Mattson M.P.
        • Cutler R.G.
        • Camandola S.
        Energy intake and amyotrophic lateral sclerosis.
        Neuromolecular Med. 2007; 9: 17-20
        • Dupuis L.
        • Oudart H.
        • René F.
        • et al.
        Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.
        Proc Natl Acad Sci U S A. 2004; 27: 11159-11164
        • Marin B.
        • Desport J.C.
        • Kajeu P.
        • et al.
        Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients.
        J Neurol Neurosurg Psychiatry. 2011; 82: 628-634
        • Paganoni S.
        • Deng J.
        • Jaffa M.
        • et al.
        Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.
        Muscle Nerve. 2011; 44: 20-24
        • Lindauer E.
        • Dupuis L.
        • Müller H.P.
        • et al.
        Adipose tissue distribution predicts survival in amyotrophic lateral sclerosis.
        PLoS One. 2013; 8: e67783
        • Körner S.
        • Hendricks M.
        • Kollewe K.
        • et al.
        Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options.
        BMC Neurol. 2013; 13: 84
      3. Symptom management and end of life care, in press.

        • Luu L.C.T.
        • Kasarskis E.J.
        • Tandan R.
        Nutritional treatment: theoretical and practical issues.
        in: Mitsumoto H. Przedborski S. Gordon P.H. Amyotrophic lateral sclerosis. Taylor & Francis, New York2006: 721-735
        • Kasarskis E.J.
        • Mendiondo M.S.
        • Wells S.
        • ALS Nutrition/NIPPV Study Group
        • et al.
        The ALS Nutrition/NIPPV Study: design, feasibility, and initial results.
        Amyotroph Lateral Scler. 2011; 12: 17-25
        • Kasarskis E.J.
        • Mendiondo M.S.
        • Matthews D.E.
        • ALS Nutrition/NIPPV Study Group
        • et al.
        Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.
        Am J Clin Nutr. 2014; 99: 792-803
      4. Available at: https://mednet.mc.uky.edu/alscalculator/. Accessed February 21, 2015.

        • Zhao Z.
        • Lange D.J.
        • Voustianiouk A.
        • et al.
        A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis.
        BMC Neurosci. 2006; 7: 29
        • Dorst J.
        • Cypionka J.
        • Ludolph A.C.
        High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study.
        Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 533-536
        • Wills A.M.
        • Hubbard J.
        • Macklin E.A.
        • MDA Clinical Research Network
        • et al.
        Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
        Lancet. 2014; 383: 2065-2072
        • Yip P.K.
        • Pizzasegola C.
        • Gladman S.
        • et al.
        The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis.
        PLoS One. 2013; 8: e61626
        • Mathus-Vliegen L.M.
        • Louwerse L.S.
        • Merkus M.P.
        • et al.
        Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function.
        Gastrointest Endosc. 1994; 40: 463-469
        • Mazzini L.
        • Corrà T.
        • Zaccala M.
        • et al.
        Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis.
        J Neurol. 1995; 242: 695-698
        • Dorst J.
        • Dupuis L.
        • Petri S.
        • et al.
        Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study.
        J Neurol. 2015; 262: 849-858
        • Chio A.
        • Galletti R.
        • Finocchiaro C.
        • et al.
        Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS.
        J Neurol Neurosurg Psychiatry. 2004; 75: 645-647
      5. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm. Accessed February 14, 2015.

        • Bradley W.G.
        • Anderson F.
        • Gowda N.
        • et al.
        Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5: 240-244
        • Rosenfeld J.
        • Ellis A.
        Nutrition and dietary supplements in motor neuron disease.
        Phys Med Rehabil Clin N Am. 2008; 19: 573
        • ALSUntangled Group
        ALS Untangled No. 20: the Deanna protocol.
        Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 319-323
      6. Available at: http://www.winningthefight.org/t/deanna-protocol. Accessed February 21, 2015.

        • Ari C.
        • Poff A.M.
        • Held H.E.
        • et al.
        Metabolic therapy with Deanna Protocol supplementation delays disease, progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model.
        PLoS One. 2014; 9: e103526
        • Ludolph A.
        • Bendotti C.
        • Blaugrund E.
        • et al.
        Guidelines for preclinical animal research in ALS/MND: a consensus meeting.
        Amyotroph Lateral Scler. 2010; 11: 38-45
        • Xu Z.
        • Chen S.
        • Li X.
        • et al.
        Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis.
        Neurochem Res. 2006; 31: 1263-1269
        • Matthews R.T.
        • Yang L.
        • Browne S.
        • et al.
        Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.
        Proc Natl Acad Sci U S A. 1998; 95: 8892-8897
        • Ferrante K.L.
        • Shefner J.
        • Zhang H.
        • et al.
        Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
        Neurology. 2005; 65: 1834-1836
        • Kaufmann P.
        • Thompson J.L.
        • Levy G.
        • et al.
        Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
        Ann Neurol. 2009; 66: 235-244
        • Adhihetty P.J.
        • Beal M.F.
        Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.
        Neuromolecular Med. 2008; 10: 275-290
        • Andreassen O.A.
        • Jenkins B.G.
        • Dedeoglu A.
        • et al.
        Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.
        J Neurochem. 2001; 77: 383-390
        • Derave W.
        • Van Den Bosch L.
        • Lemmens G.
        • et al.
        Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment.
        Neurobiol Dis. 2003; 13: 264-272
        • Rosenfeld J.
        • King R.M.
        • Jackson C.E.
        • et al.
        Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.
        Amyotroph Lateral Scler. 2008; 9: 266-272
        • Groeneveld G.J.
        • Veldink J.H.
        • van der Tweel I.
        • et al.
        A randomized sequential trial of creatine in amyotrophic lateral sclerosis.
        Ann Neurol. 2003; 53: 437-445
        • Pastula D.M.
        • Moore D.H.
        • Bedlack R.S.
        Creatine for amyotrophic lateral sclerosis/motor neuron disease.
        Cochrane Database Syst Rev. 2012; (CD005225)
        • Atassi N.
        • Ratai E.M.
        • Greenblatt D.J.
        • et al.
        A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis.
        Amyotroph Lateral Scler. 2010; 11: 508-513
        • Erb M.
        • Hoffmann-Enger B.
        • Deppe H.
        • et al.
        Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I.
        PLoS One. 2012; 7: e36153
        • Parkinson M.H.
        • Schulz J.B.
        • Giunti P.
        Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
        J Neurochem. 2013; 126: 125-141
        • Jaber S.
        • Polster B.M.
        Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?.
        J Bioenerg Biomembr. 2015; 47: 111-118
        • Gülçin I.
        Antioxidant and antiradical activities of L-carnitine.
        Life Sci. 2006; 18: 803-811
        • Kira Y.
        • Nishikawa M.
        • Ochi A.
        • et al.
        L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis.
        Brain Res. 2006; 1070: 206-214
        • Beghi E.
        • Pupillo E.
        • Bonito V.
        • Italian ALS Study Group
        • et al.
        Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.
        Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 397-405
        • Calder P.C.
        • Yaqoob P.
        Omega-3 polyunsaturated fatty acids and human health outcomes.
        Biofactors. 2009; 35: 266-272
        • Dyall S.C.
        • Michael-Titus A.T.
        Neurological benefits of omega-3 fatty acids.
        Neuromolecular Med. 2008; 10: 219-235
        • Fitzgerald K.C.
        • O'Reilly É.J.
        • Falcone G.J.
        • et al.
        Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis.
        JAMA Neurol. 2014; 71: 1102-1110
        • Mancuso R.
        • del Valle J.
        • Modol L.
        • et al.
        Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice.
        Neurotherapeutics. 2014; 11: 419-432
        • Song L.
        • Chen L.
        • Zhang X.
        • et al.
        Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
        Biomed Res Int. 2014; 2014: 483501
        • Mancuso R.
        • Del Valle J.
        • Morell M.
        • et al.
        Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity?.
        Orphanet J Rare Dis. 2014; 9: 78
        • Park E.J.
        • Pezzuto J.M.
        The pharmacology of resveratrol in animals and humans.
        Biochim Biophys Acta. 2015; 31: S0925-S4439
        • Molina J.A.
        • de Bustos F.
        • Jiménez-Jiménez F.J.
        • et al.
        Serum levels of beta-carotene, alpha-carotene, and vitamin A in patients with amyotrophic lateral sclerosis.
        Acta Neurol Scand. 1999; 99: 315-317
        • Crochemore C.
        • Virgili M.
        • Bonamassa B.
        • et al.
        Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis.
        Muscle Nerve. 2009; 39: 548-552
        • Mattson M.P.
        • Shea T.B.
        Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders.
        Trends Neurosci. 2003; 26: 137-146
        • Zoccolella S.
        • Simone I.L.
        • Lamberti P.
        • et al.
        Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis.
        Neurology. 2008; 70: 222-225
        • Valentino F.
        • Bivona G.
        • Butera D.
        • et al.
        Elevated cerebrospinal fluid and plasma homocysteine levels in ALS.
        Eur J Neurol. 2010; 17: 84-89
        • Zhang X.
        • Chen S.
        • Li L.
        • et al.
        Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice.
        Neuropharmacology. 2008; 54: 1112-1119
        • Hemendinger R.A.
        • Armstrong 3rd, E.J.
        • Brooks B.R.
        Methyl vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death.
        Toxicol Appl Pharmacol. 2011; 251: 217-225
        • Song L.
        • Gao Y.
        • Zhang X.
        • et al.
        Galactooligosaccharide improves the animal survival and alleviates motor neuron death in SOD1G93A mouse model of amyotrophic lateral sclerosis.
        Neuroscience. 2013; 246: 281-290
        • Poloni M.
        • Patrini C.
        • Rocchelli B.
        • et al.
        Thiamin monophosphate in the CSF of patients with amyotrophic lateral sclerosis.
        Arch Neurol. 1982; 39: 507-509
        • Poloni M.
        • Mazzarello P.
        • Patrini C.
        • et al.
        Inversion of T/TMP ratio in ALS: a specific finding?.
        Ital J Neurol Sci. 1986; 7: 333-335
        • Moges H.
        • Vasconcelos O.M.
        • Campbell W.W.
        • et al.
        Light therapy and supplementary riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS).
        Lasers Surg Med. 2009; 41: 52-59
        • Fitzgerald K.C.
        • O'Reilly E.J.
        • Fondell E.
        • et al.
        Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohort studies.
        Ann Neurol. 2013; 73: 236-245
        • Karam C.
        • Scelsa S.N.
        Can vitamin D delay the progression of ALS?.
        Med Hypotheses. 2011; 76: 643-645
        • Camu W.
        • Tremblier B.
        • Plassot C.
        • et al.
        Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis.
        Neurobiol Aging. 2014; 35: 1198-1205
        • Gianforcaro A.
        • Hamadeh M.J.
        Dietary vitamin D3 supplementation at 10x the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study.
        CNS Neurosci Ther. 2012; 18: 547-557
        • Gianforcaro A.
        • Solomon J.A.
        • Hamadeh M.J.
        Vitamin D(3) at 50x AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in females.
        PLoS One. 2013; 8: e30243
        • Solomon J.A.
        • Gianforcaro A.
        • Hamadeh M.J.
        Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis.
        PLoS One. 2011; 6: e29354
        • Karam C.
        • Barrett M.J.
        • Imperato T.
        • et al.
        Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis.
        J Clin Neurosci. 2013; 20: 1550-1553
        • ALSUntangled Group
        ALSUntangled No. 24: vitamin D.
        Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15: 318-320
        • Gurney M.E.
        • Cutting F.B.
        • Zhai P.
        • et al.
        Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.
        Ann Neurol. 1996; 39: 147-157
        • Desnuelle C.
        • Dib M.
        • Garrel C.
        • et al.
        A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2: 9-18
        • Graf M.
        • Ecker D.
        • Horowski R.
        • et al.
        High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
        J Neural Transm. 2005; 112: 649-660
        • Wang H.
        • O'Reilly E.J.
        • Weisskopf M.G.
        • et al.
        Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies.
        Am J Epidemiol. 2011; 173: 595-602
        • Carter G.T.
        • Bedlack R.
        • Hardiman O.
        • ALSUntangled Group
        • et al.
        • Collaborators (79)
        ALSUntangled No. 16: cannabis.
        Amyotroph Lateral Scler. 2012; 13: 400-404
        • Kim K.
        • Moore D.H.
        • Makriyannis A.
        • et al.
        AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.
        Eur J Pharmacol. 2006; 542: 100-105
        • Shoemaker J.L.
        • Seely K.A.
        • Reed R.L.
        • et al.
        The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
        J Neurochem. 2007; 101: 87-98
        • Raman C.
        • McAllister S.D.
        • Rizvi G.
        • et al.
        Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5: 33-39
        • Weydt P.
        • Hong S.
        • Witting A.
        • et al.
        Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 182-184
        • Rossi S.
        • De Chiara V.
        • Musella A.
        • et al.
        Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis.
        Amyotroph Lateral Scler. 2009; 19: 1-8
        • Bilsland L.G.
        • Dick J.R.
        • Pryce G.
        • et al.
        Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.
        FASEB J. 2006; 20: 1003-1005
        • Bilsland L.G.
        • Greensmith L.
        The endocannabinoid system in amyotrophic lateral sclerosis.
        Curr Pharm Des. 2008; 14: 2306-2316
        • Zhao P.
        • Ignacio S.
        • Beattie E.C.
        • et al.
        Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.
        Eur J Neurosci. 2008; 27: 572-579
        • Witting A.
        • Weydt P.
        • Hong S.
        • et al.
        Endocannabinoids accumulate in spinal cord of SOD1 transgenic mice.
        J Neurochem. 2004; 89: 1555-1557
        • Carter G.T.
        • Rosen B.S.
        Marijuana in the management of amyotrophic lateral sclerosis.
        Am J Hosp Palliat Care. 2001; 18: 264-270
        • Gelinas D.
        • Miller R.G.
        • Abood M.E.
        A pilot study of safety and tolerability of Delta 9-THC (Marinol) treatment for ALS.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2002; 3: 23
        • Amtmann D.
        • Weydt P.
        • Johnson K.L.
        • et al.
        Survey of cannabis use in patients with amyotrophic lateral sclerosis.
        Am J Hosp Palliat Care. 2004; 21: 95-104
        • Carter G.T.
        • Abood M.E.
        • Aggarwal S.K.
        • et al.
        Cannabis and amyotrophic lateral sclerosis: practical and hypothetical applications, and a call for clinical trials.
        Am J Hosp Palliat Care. 2010; 27: 347-356
        • Di Iorio G.
        • Lupi M.
        • Sarchione F.
        • et al.
        The endocannabinoid system: a putative role in neurodegenerative diseases.
        Int J High Risk Behav Addict. 2013; 2: 100-106
        • Abood M.E.
        Molecular biology of cannabinoid receptors.
        Handb Exp Pharmacol. 2005; 168: 81-115
        • McAllister S.D.
        • Hurst D.P.
        • Barnett-Norris J.
        • et al.
        Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation.
        J Biol Chem. 2004; 279: 48024-48037
        • Kapur A.
        • Samaniego P.
        • Thakur G.A.
        • et al.
        Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
        J Pharmacol Exp Ther. 2008; 325: 341-348
        • Anavi-Goffer S.
        • Fleischer D.
        • Hurst D.P.
        • et al.
        Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms.
        J Biol Chem. 2007; 282: 25100-25113
        • Abood M.E.
        • Rizvi G.
        • Sallapudi N.
        • et al.
        Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.
        Neurosci Lett. 2001; 309: 197-201
        • Klein T.W.
        • Lane B.
        • Newton C.A.
        • et al.
        The cannabinoid system and cytokine network.
        Proc Soc Exp Biol Med. 2000; 225: 1-8
        • Pertwee R.G.
        Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.
        Expert Opin Investig Drugs. 2000; 9: 1553-1571
        • Aizpurua-Olaizola O.
        • Omar J.
        • Navarro P.
        • et al.
        Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry.
        Anal Bioanal Chem. 2014; 406: 7549-7560
        • Mechoulam R.
        • Hanuš L.O.
        • Pertwee R.
        • et al.
        Early phytocannabinoid chemistry to endocannabinoids and beyond.
        Nat Rev Neurosci. 2014; 15: 757-764
        • De Petrocellis L.
        • Di Marzo V.
        Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
        J Neuroimmune Pharmacol. 2010; 5: 103-121
        • Russo E.B.
        Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
        Br J Pharmacol. 2011; 163: 1344-1364
        • Pertwee R.G.
        Pharmacological actions of cannabinoids.
        Handb Exp Pharmacol. 2005; 168: 1-51
        • Gonçalves T.C.
        • Londe A.K.
        • Albano R.I.
        • et al.
        Cannabidiol and endogenous opioid peptide-mediated mechanisms modulate antinociception induced by transcutaneous electrostimulation of the peripheral nervous system.
        J Neurol Sci. 2014; 347: 82-89
        • Stout S.M.
        • Cimino N.M.
        Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
        Drug Metab Rev. 2014; 46: 86-95
        • Castaneto M.S.
        • Gorelick D.A.
        • Desrosiers N.A.
        • et al.
        Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
        Drug Alcohol Depend. 2014; 1: 12-41
        • Adams I.B.
        • Martin B.R.
        Cannabis: pharmacology and toxicology in animals and humans.
        Addiction. 1996; 91: 1585-1614
        • Romero J.
        • Orgado J.M.
        Cannabinoids and neurodegenerative diseases.
        CNS Neurol Disord Drug Targets. 2009; 8: 440-450
        • Meng I.D.
        • Manning B.H.
        • Martin W.J.
        • et al.
        An analgesia circuit activated by cannabinoids.
        Nature. 1998; 395: 381-383
        • Zeltser R.
        • Seltzer Z.
        • Eisen A.
        • et al.
        Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties.
        Pain. 1991; 47: 95-103
        • Elikottil J.
        • Gupta P.
        • Gupta K.
        The analgesic potential of cannabinoids.
        J Opioid Manag. 2009; 5: 341-357
        • Martín-Sánchez E.
        • Furukawa T.A.
        • Taylor J.
        • et al.
        Systematic review and meta-analysis of cannabis treatment for chronic pain.
        Pain Med. 2009; 10: 1353-1368
        • Lynch M.E.
        • Campbell F.
        Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
        Br J Clin Pharmacol. 2011; 72: 735-744
        • Fine P.G.
        • Rosenfeld M.J.
        The endocannabinoid system, cannabinoids, and pain.
        Rambam Maimonides Med J. 2013; 4: e0022
        • Fitzgerald P.B.
        • Williams S.
        • Daskalakis Z.J.
        A transcranial magnetic stimulation study of the effects of cannabis use on motor cortical inhibition and excitability.
        Neuropsychopharmacology. 2009; 34: 2368-2375
        • Lichtman A.H.
        • Martin B.R.
        Spinal and supraspinal components of cannabinoid-induced antinociception.
        J Pharmacol Exp Ther. 1991; 258: 517-523
        • Collin C.
        • Davies P.
        • Mutiboko I.K.
        • Sativex Spasticity in MS Study Group
        • et al.
        Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
        Eur J Neurol. 2007; 14: 290-296
        • Corey-Bloom J.
        • Wolfson T.
        • Gamst A.
        • et al.
        (2012) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
        CMAJ. 2012; 184: 1143-1150
        • Koppel B.S.
        • Brust J.C.
        • Fife T.
        • et al.
        Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.
        Neurology. 2014; 82: 1556-1563
        • Yadav V.
        • Bever Jr., C.
        • Bowen J.
        • et al.
        Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.
        Neurology. 2014; 82: 1083-1092
        • Carter G.T.
        • Weydt P.
        • Kyashna-Tocha M.
        • et al.
        Medical marijuana: rational guidelines for dosing.
        IDrugs. 2004; 7: 464-470
      7. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol[(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
        Fed Regist. 1999; 64: 35928-35930
        • Aggarwal S.K.
        • Carter G.T.
        • Sullivan M.D.
        • et al.
        Enforcement in a series of medical cannabis patients.
        J Nerv Ment Dis. 2013; 201: 292-303
      8. Available at: http://en.wikipedia.org/wiki/Acupuncture. Accessed March 3, 2015.

        • Ernst E.
        Acupuncture-a critical analysis.
        J Intern Med. 2006; 259: 125-137
      9. Available at: http://www.drmihaly-acupuncture.com/chinese-scalp-acupuncture-als.html. Accessed March 7, 2015.

      10. Available at: http://www.hughsacupuncture.com/als-treatment-by-acupuncture-and-traditional-chinese-medicine/. Accessed March 7, 2015.

      11. Available at: http://www.taoiststudy.com/content/use-qigong-herbal-medicine-achieve-cure-als. Accessed March 7, 2015.

        • Ramey D.
        Acupuncture points and meridians do not exist.
        Sci Rev Alternative Med. 2001; 5: 143-148
        • Gorski D.
        Integrative oncology: really the best of both worlds?.
        Nat Rev Cancer. 2014; 2014: 692-700
        • Dawidson I.
        • Angmar-Mansson B.
        • Blom M.
        • et al.
        The influence of sensory stimulation (acupuncture) on the release of neuropeptides in the saliva of healthy subjects.
        Life Sci. 1998; 63: 659-674
        • Yu J.S.
        • Zeng B.Y.
        • Hsieh C.L.
        Acupuncture stimulation and neuroendocrine regulation.
        Int Rev Neurobiol. 2013; 111: 125-140
        • Han J.-S.
        Acupuncture and endorphins.
        Neurosci Lett. 2004; 361: 236-240
        • Lee H.J.
        • Lee J.H.
        • Lee E.O.
        • et al.
        Substance P and beta-endorphin mediate electro-acupuncture induced analgesia in mouse cancer pain model.
        J Exp Clin Cancer Res. 2009; 28: 102
        • Eisenstein T.
        Opioids and the immune system: what is their role?.
        Br J Pharmacol. 2011; 16: 1826-1828
        • Panerai A.E.
        • Radulovic J.
        • Monastra G.
        • et al.
        Beta-endorphin concentrations in brain areas and peritoneal macrophages in rats susceptible and resistant to experimental allergic encephalomyelitis: a possible relationship between tumor necrosis factor alpha and opioids in the disease.
        J Neuroimmunol. 1994; 51: 169-176
        • McCarthy L.
        • Wetzel M.
        • Sliker J.K.
        • et al.
        Opioids, opioid receptors and the immune response.
        Drug Alcohol Depend. 2001; 62: 111-123
        • Murdock B.J.
        • Bender D.E.
        • Segal B.M.
        • et al.
        The dual roles of immunity and ALS: injury overrides protection.
        Neurobiol Dis. 2015; 77: 1-12
        • Hooten K.G.
        • Beers D.R.
        • Zhao W.
        • et al.
        Protective and toxic neuroinflammation in amyotrophic lateral sclerosis.
        Neurotherapeutics. 2015; 12: 364-375
        • Napadow V.
        • Makris N.
        • Liu J.
        • et al.
        Effects of electroacupuncture versus manual acupuncture on the human brain as measured by fMRI.
        Hum Brain Mapp. 2005; 24: 193-205
        • Wu M.T.
        • Sheen J.M.
        • Chuang K.H.
        • et al.
        Neuronal specificity of acupuncture response: an fMRI study with electroacupuncture.
        Neuroimage. 2002; 16: 1028-1037
        • Fang J.L.
        • Krings T.
        • Weidemann J.
        • et al.
        Functional MRI in healthy subjects during acupuncture; different effects of needle rotation in real and false acupoints.
        Neuroradiology. 2004; 46: 359-362
        • Cho Z.H.
        • Chung S.C.
        • Jones J.P.
        • et al.
        New findings of the correlation between acupoints and corresponding brain cortices using functional MRI.
        Proc Natl Acad Sci U S A. 1998; 95: 2670-2673
        • Yan B.
        • Li K.
        • Xu J.
        • et al.
        Acupoint-specific fMRI patterns in human brain.
        Neurosci Lett. 2005; 383: 236-240
        • Zillstra F.
        • van den Berg-de-Lange I.
        • Huygen F.
        • et al.
        Anti-inflammatory actions of acupuncture.
        Mediators Inflamm. 2003; 12: 59-69
        • Kim S.T.
        • Doo A.R.
        • Kim S.R.N.
        • et al.
        Acupuncture suppresses kainic acid-induced neuronal death and inflammatory events in mouse hippocampus.
        J Physiol Sci. 2012; 62: 377-383
        • Yang E.
        • Jiang J.
        • Lee S.
        • et al.
        Electroacupuncture reduces neuroinflammatory responses in symptomatic amyotrophic lateral sclerosis model.
        J Neuroimmunol. 2010; 223: 84-91
        • Jiang J.
        • Yang E.
        • Baek M.
        • et al.
        Anti-inflammatory effects of electroacupuncture in the respiratory system of a symptomatic amyotrophic lateral sclerosis model.
        Neurodegener Dis. 2011; 8: 504-514
        • Chapman C.
        • Benedetti C.
        • Colpitts Y.
        • et al.
        Naloxone fails to reverse pain thresholds elevated by acupuncture.
        Pain. 1983; 16: 13-31
        • Lam M.
        • Galvin R.
        • Curry P.
        Effectiveness of acupuncture for nonspecific chronic low back pain: a systematic review and meta-analysis.
        Spine (Phila Pa 1976). 2013; 38: 2124-2138
        • Wilke J.
        • Vogt L.
        • Niederer D.
        • et al.
        Short-term effects of acupuncture and stretching on myofascial trigger point pain of the neck: a blinded, placebo-controlled RCT.
        Complement Ther Med. 2014; 22: 835-841
        • Crespin D.J.
        • Griffin K.H.
        • Johnson J.R.
        • et al.
        Acupuncture provides short-term pain relief for patients in a total joint replacement program.
        Pain Med. 2015; 16: 1195-1203
        • Iacobone M.
        • Citton M.
        • Zanella S.
        • et al.
        The effects of acupuncture after thyroid surgery: a randomized, controlled trial.
        Surgery. 2014; 156 ([discussion: 1612–3]): 1605-1612
        • Lim S.M.
        • Yoo J.
        • Lee E.
        • et al.
        Acupuncture for spasticity after stroke: a systematic review and meta-analysis of randomized controlled trials.
        Evid Based Complement Alternat Med. 2015; 2015: 870398
        • Lee S.
        • Kim S.
        The effects of sa-am acupuncture treatment on respiratory parameters in amyotrophic lateral sclerosis.
        Evid Based Complement Alternat Med. 2013; 2013: 506317
        • Yongde C.
        Formulating a therapeutic program with the governing vessel in treating 46 cases of ALS.
        Shanghai Journal of Moxibustion. 1998; 17: 43
        • Yongde C.
        Clinical observation on 46 cases of ALS in consideration of the treatment principal breaking through the Dumai.
        Zhejiang Journal of Integrating Traditional Chinese and Western Medicine. 1999; 9: 16-17
      12. Available at: http://www.itmonline.org/arts/als.htm. Accessed March 19, 2015.

        • Liang S.
        • Christner D.
        • DuLaux S.
        • et al.
        Significant neurological improvement in two patients with amyotrophic lateral sclerosis after 4 weeks of treatment with acupuncture injection point therapy using enercel.
        J Acupunct Meridian Stud. 2011; 4: 257-261
        • ALSUntangled Group
        ALSUntangled 28: acupuncture.
        Amyotroph Lateral Scler Frontotemporal Degener. 2015; 16: 286-289
      13. Available at: http://www.patientslikeme.com/treatment_evaluations/browse?brand=f&condition_id=9&id=213-acupuncture-side-effects-and-efficacy. Accessed March 21, 2015.

        • Ernst E.
        • Zhang J.
        Cardiac tamponade caused by acupuncture: a review of the literature.
        Int J Cardiol. 2011; 149: 287-289
        • Demir M.
        • Oruc M.
        • Dalli A.
        • et al.
        A rare complication of acupuncture: pneumothorax.
        Tuberk Toraks. 2014; 62: 316-318
        • Ernst E.
        • Sherman K.J.
        Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies.
        J Gastroenterol Hepatol. 2003; 18: 1231-1236
        • White A.
        • Hayhoe S.
        • Hart A.
        • et al.
        Adverse events following acupuncture: a prospective survey of 32000 consultations with doctors and physiotherapists.
        BMJ. 2001; 323: 485-486
        • Melchart D.
        • Weidenhammer W.
        • Streng A.
        • et al.
        Prospective investigation of adverse events in 97,733 patients.
        Arch Intern Med. 2004; 164: 104-105
        • MacPherson H.
        • Scullion A.
        • Thomas K.J.
        • et al.
        Patient reports of adverse events associated with acupuncture treatment: a prospective national survey.
        Qual Saf Health Care. 2004; 13: 349-355
        • Villarruz M.V.
        • Dans A.
        • Tan F.
        Chelation therapy for atherosclerotic cardiovascular disease.
        Cochrane Database Syst Rev. 2002; (CD002785)
        • Seely D.M.
        • Wu P.
        • Mills E.J.
        EDTA chelation therapy for cardiovascular disease: a systematic review.
        BMC Cardiovasc Disord. 2005; 5: 32
        • Sutedja N.A.
        • Veldink J.H.
        • Fischer K.
        • et al.
        Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review.
        Amyotroph Lateral Scler. 2009; 10: 302-309
        • Callaghan B.
        • Feldman D.
        • Gruis K.
        • et al.
        The association of exposure to lead, mercury, and selenium in the development of amyotrophic lateral sclerosis and the epigenetic implications.
        Neurodegener Dis. 2011; 8: 1-8
        • Praline J.
        • Guennoc A.M.
        • Limousin N.
        • et al.
        ALS and mercury intoxication: a relationship?.
        Clin Neurol Neurosurg. 2007; 109: 880-883
        • Couratier P.
        • Bernet-Bernady P.
        • Truong T.
        • et al.
        Lead intoxication and amyotrophic lateral sclerosis.
        Rev Neurol (Paris). 1998; 154 ([in French]): 345-347
        • Louwerse E.S.
        • Buchet J.P.
        • Van Dijk M.A.
        • et al.
        Urinary excretion of lead and mercury after oral administration of meso-2,3-dimercaptosuccinic acid in patients with motor neurone disease.
        Int Arch Occup Environ Health. 1995; 67: 135-138
      14. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm. Accessed March 25, 2015.

        • Cleland J.A.
        • Price D.B.
        • Lee A.J.
        • et al.
        A pragmatic, three-arm randomised controlled trial of spiritual healing for asthma in primary care.
        Br J Gen Pract. 2006; 56: 444-449
        • Benson H.
        • Dusek J.A.
        • Sherwood J.B.
        • et al.
        Study of the Therapeutic Effects of Intercessory Prayer (STEP) in cardiac bypass patients: a multicenter randomized trial of uncertainty and certainty of receiving intercessory prayer.
        Am Heart J. 2006; 151: 934-942
        • O'Mathúna D.P.
        • Ashford R.L.
        Therapeutic touch for healing acute wounds.
        Cochrane Database Syst Rev. 2014; (CD002766)
        • Kundu A.
        • Lin Y.
        • Oron A.P.
        • et al.
        Reiki therapy for postoperative oral pain in pediatric patients: pilot data from a double-blind, randomized clinical trial.
        Complement Ther Clin Pract. 2014; 20: 21-25
        • FitzHenry F.
        • Wells N.
        • Slater V.
        • et al.
        A randomized placebo-controlled pilot study of the impact of healing touch on fatigue in breast cancer patients undergoing radiation therapy.
        Integr Cancer Ther. 2014; 13: 105-113
        • Johnston C.
        • Campbell-Yeo M.
        • Rich B.
        • et al.
        Therapeutic touch is not therapeutic for procedural pain in very preterm neonates: a randomized trial.
        Clin J Pain. 2013; 29: 824-829
        • ALSUntangled Group
        ALSUntangled 12: Dean Kraft, energy healer.
        Amyotroph Lateral Scler. 2011; 12: 389-391
        • Miyoshi K.
        • Ohyagi Y.
        • Amano T.
        • et al.
        A patient with motor neuron syndrome clinically similar to amyotrophic lateral sclerosis presenting a spontaneous recovery.
        Rinsho Shinkeigaku. 2000; 40: 1090-1095
        • Tsai C.P.
        • Ho H.H.
        • Yen D.J.
        • et al.
        Reversible motor neuron disease.
        Eur Neurol. 1993; 33: 387-389
        • Tucker T.
        • Layzer R.
        • Miller R.
        • et al.
        Subacute, reversible motor neuron disease.
        Neurology. 1991; 41: 1541-1544
        • Ernst E.
        Distant healing–an “update” of a systematic review.
        Wien Klin Wochenschr. 2003; 115: 241-245
        • Ernst E.
        Complementary treatment: who cares how it works, as long as it does?.
        Lancet Oncol. 2005; 6: 131-132
        • Ernst E.
        Spiritual healing: more than meets the eye.
        J Pain Symptom Manage. 2006; 32: 393-395
        • Emanuel E.
        • Emanuel L.
        Four models of the physician-patient relationship.
        JAMA. 1992; 267: 2221-2226
        • O’Brien M.R.
        Information-seeking behavior among people with motor neuron disease.
        Br J Nurs. 2004; 13: 964-968
        • Osman H.
        History and development of the doctrine of informed consent.
        Int Electron J Health Educ. 2001; 4: 41-47
        • Bedlack R.
        • Hardiman O.
        ALSUntangled: a scientific approach to off-label treatment options for patients with ALS using tweets and twitters.
        Amyotroph Lateral Scler. 2009; 3: 129-130
        • Deber R.
        • Kraetschmer N.
        • Urowitz S.
        • et al.
        Do people want to be autonomous patients? Preferred roles in treatment decision-making in several patient populations.
        Health Expect. 2007; 3: 248-258
        • Murray E.
        • Pollck L.
        • White M.
        • et al.
        Clinical decision-making: physicians’ preferences and experiences.
        BMC Fam Pract. 2007; 8: 10
        • Joosten E.
        • DeFuentes-Merillas L.
        • de Weert G.
        • et al.
        Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status.
        Psychother Psychosom. 2008; 77: 219-226
        • The ALSUntangled Group
        ALSUntangled: introducing the table of evidence.
        Amyotroph Lateral Scler Frontotemporal Degener. 2015; 16: 142-145
        • ALSUntangled Group
        ALSUntangled No. 19: sodium chlorite.
        Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 236-238